Keywords
Last Name
Institution

Darlene H. Moak

Title
InstitutionMedical University of South Carolina
DepartmentPsychiatry and Behavioral Sciences
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Baros AM, Latham PK, Moak DH, Voronin K, Anton RF. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603. PMID: 17374038.
      View in: PubMed
    2. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006 Feb; 26(1):13-20. PMID: 16415699.
      View in: PubMed
    3. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57. PMID: 16012278.
      View in: PubMed
    4. Malcolm R, LaRowe S, Cochran K, Moak D, Herron J, Brady K, Hedden S, Woolson R, Halushka P. A controlled trial of amlodipine for cocaine dependence: a negative report. J Subst Abuse Treat. 2005 Mar; 28(2):197-204. PMID: 15780550.
      View in: PubMed
    5. Moak DH. Assessing the efficacy of medical treatments for alcohol use disorders. Expert Opin Pharmacother. 2004 Oct; 5(10):2075-89. PMID: 15461543.
      View in: PubMed
    6. Covault J, Pettinati H, Moak D, Mueller T, Kranzler HR. Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. Am J Med Genet B Neuropsychiatr Genet. 2004 May 15; 127B(1):42-7. PMID: 15108178.
      View in: PubMed
    7. Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI. Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcohol Clin Exp Res. 2004 Feb; 28(2):302-12. PMID: 15112938.
      View in: PubMed
    8. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40. PMID: 14722705.
      View in: PubMed
    9. Moak DH, Anton RF, Latham PK, Voronin KE, Waid RL, Durazo-Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003 Dec; 23(6):553-62. PMID: 14624185.
      View in: PubMed
    10. Nellissery M, Feinn RS, Covault J, Gelernter J, Anton RF, Pettinati H, Moak D, Mueller T, Kranzler HR. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res. 2003 Sep; 27(9):1402-8. PMID: 14506400.
      View in: PubMed
    11. Malcolm R, Book SW, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict. 2002; 11(3):247-9. PMID: 12202017.
      View in: PubMed
    12. Moak DH, Anton RF, Latham PK. Further validation of the Obsessive-Compulsive Drinking Scale (OCDS). Relationship to alcoholism severity. Am J Addict. 1998; 7(1):14-23. PMID: 9522003.
      View in: PubMed
    Moak's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description